Abera Bioscience AB (8WK)

Overview

Abera Bioscience AB is an innovative platform and vaccine development company engaged in the research, design, and development of vaccines and immunotherapies. Leveraging its proprietary vaccine delivery platform, known as BERA, the company focuses on the surface display of antigens using outer membrane vesicles derived from genetically optimized gram-negative bacteria. This unique approach allows for the development of highly targeted and effective vaccines and therapies. Based in Uppsala, Sweden, and operating internationally since its incorporation in 2012, Abera Bioscience is forefront in addressing some of the most challenging diseases through its cutting-edge vaccines and immunotherapy development.

Products and Services

• Universal Pneumococcal Vaccine:

The leading vaccine candidate from Abera Bioscience, developed using the BERA platform, aims to provide broad protection against pneumococcal infections. This universal vaccine targets multiple strains of the pneumococcus bacterium, potentially offering wider protection than current vaccines.

• Immuno-Oncology Projects:

The company's explorations into immuno-oncology focus on harnessing the body's immune system to fight cancer. By developing vaccine-based therapies, Abera Bioscience aims to introduce new, innovative solutions to cancer treatment, focusing on the immune system's ability to target and destroy cancer cells.

• Chlamydia Vaccine:

Addressing one of the most common sexually transmitted infections, Abera Bioscience is working on a vaccine for Chlamydia. This project highlights the company's commitment to tackling infectious diseases with significant global impact, aiming to reduce incidence and complications associated with Chlamydia infections.

• ETEC (Enterotoxigenic Escherichia coli) Vaccine:

Aiming to combat diarrheal diseases caused by ETEC bacteria, a leading cause of childhood mortality in low-income countries, this vaccine candidate represents Abera Bioscience's commitment to addressing global health challenges, particularly in developing regions.

• COVID-19 Vaccine:

In response to the global pandemic, Abera Bioscience has applied its innovative platform to the development of a COVID-19 vaccine. This project demonstrates the company's agility and commitment to contributing to global health crises by leveraging its proprietary technologies to develop a potent and safe vaccine against the novel coronavirus.

• Tuberculosis (TB) Vaccine:

Given the ongoing global health challenge posed by TB, Abera Bioscience is also focusing on the development of a new vaccine against tuberculosis. This effort aligns with the global health community's goal to reduce TB incidence and mortality, showcasing Abera Bioscience's dedication to combating persistent infectious diseases.